fabiocrognale, Autore presso Nouscom

Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an ‘off-the shelf’ Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer

BASEL, Switzerland – 15th November 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced the first patient has [...]

Nouscom’s Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors

Initial data from Phase 1b trial evaluating NOUS-PEV in combination with pembrolizumab to be presented at SITC 2022 BASEL, Switzerland – 7th November 2022 – Nouscom, a clinical stage [...]

Sven Gogov | MD

Sven Gogov, MD, is an experienced global clinical development leader bringing over 15 years of pharmaceutical oncology experience and regulatory interactions to Nouscom. Sven joined Nouscom in [...]

Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs

BASEL, Switzerland – 9th September 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced the [...]

Nouscom new Science Translational Medicine publication highlighted on Cancer Discovery #ResearchWatch

Nouscom new Science Translational Medicine publication is highlighted on Cancer Discovery #ResearchWatch, describing a novel mechanism of action driven by viral vector-based vaccine platform [...]

Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy

Research paper published in Science Translational Medicine by Nouscom and the Armenise-Harvard Laboratory of Immunoregulation at IIGM led by Luigia Pace describes how Nouscom’s adenoviral based [...]

Nouscom Announces Positive Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

NOUS-209 in combination with pembrolizumab is safe, highly immunogenic, and associated with promising early and long-term clinical efficacy in 20 MSI-H GI patients BASEL, Switzerland – 6th June [...]

Nouscom to Present Full Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

BASEL, Switzerland – 27th May 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced that full [...]

Nouscom Announces Promotion of Richard Davis to Chief Operating Officer

BASEL, Switzerland –23rd May 2022 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced the promotion [...]

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed using Nouscom’s Proprietary Viral Vector Platform

VAC85135 is a novel clinical candidate developed by Nouscom and Janssen under a multi-project agreement BASEL, Switzerland – 17th May 2022 – Nouscom, a clinical stage immuno-oncology [...]